188 related articles for article (PubMed ID: 25185738)
1. Letter: proton pump inhibitor usage still seems to reduce the risk of high-grade dysplasia and/or oesophageal adenocarcinoma in Barrett's oesophagus.
Aydin Y; Akin H
Aliment Pharmacol Ther; 2014 Oct; 40(7):859-60. PubMed ID: 25185738
[No Abstract] [Full Text] [Related]
2. Letter: proton pump inhibitor usage still seems to reduce the risk of high-grade dysplasia and/or oesophageal adenocarcinoma in Barrett's oesophagus--authors' reply.
Hvid-Jensen F; Drewes AM; Funch-Jensen P
Aliment Pharmacol Ther; 2014 Oct; 40(7):860-1. PubMed ID: 25185739
[No Abstract] [Full Text] [Related]
3. Effect of proton pump inhibitors on markers of risk for high-grade dysplasia and oesophageal cancer in Barrett's oesophagus.
Hillman LC; Chiragakis L; Shadbolt B; Kaye GL; Clarke AC
Aliment Pharmacol Ther; 2008 Feb; 27(4):321-6. PubMed ID: 18047565
[TBL] [Abstract][Full Text] [Related]
4. Proton pump inhibitor use may not prevent high-grade dysplasia and oesophageal adenocarcinoma in Barrett's oesophagus: a nationwide study of 9883 patients.
Hvid-Jensen F; Pedersen L; Funch-Jensen P; Drewes AM
Aliment Pharmacol Ther; 2014 May; 39(9):984-91. PubMed ID: 24617286
[TBL] [Abstract][Full Text] [Related]
5. Does the treatment of proton pump inhibitors reduce dysplasia or adenocarcinoma development in Barrett's esophagus?
Akın H; Aydın Y
Turk J Gastroenterol; 2017 Dec; 28(Suppl 1):S31-S32. PubMed ID: 29199164
[TBL] [Abstract][Full Text] [Related]
6. Letter: proton pump inhibitors, GERD and oesophageal adenocarcinoma.
Rosch PJ
Aliment Pharmacol Ther; 2014 Aug; 40(3):319. PubMed ID: 25040746
[No Abstract] [Full Text] [Related]
7. Letter: proton pump inhibitors, GERD and oesophageal adenocarcinoma - authors' reply.
Hvid-Jensen F; Funch-Jensen P; Drewes AM
Aliment Pharmacol Ther; 2014 Aug; 40(3):320. PubMed ID: 25040747
[No Abstract] [Full Text] [Related]
8. The Effect of Proton Pump Inhibitors on Barrett's Esophagus.
Dunbar KB; Souza RF; Spechler SJ
Gastroenterol Clin North Am; 2015 Jun; 44(2):415-24. PubMed ID: 26021202
[TBL] [Abstract][Full Text] [Related]
9. Acid suppression medications reduce risk of oesophageal adenocarcinoma in Barrett's oesophagus: a nested case-control study in US male veterans.
Tan MC; El-Serag HB; Yu X; Thrift AP
Aliment Pharmacol Ther; 2018 Aug; 48(4):469-477. PubMed ID: 29956826
[TBL] [Abstract][Full Text] [Related]
10. Proton-pump inhibitor therapy and the development of dysplasia in patients with Barrett's oesophagus.
Hillman LC; Chiragakis L; Shadbolt B; Kaye GL; Clarke AC
Med J Aust; 2004 Apr; 180(8):387-91. PubMed ID: 15089728
[TBL] [Abstract][Full Text] [Related]
11. Barrett's oesophagus and proton pump inhibitors: a pathological perspective.
Shepherd NA
Gut; 2000 Feb; 46(2):147-9. PubMed ID: 10644302
[No Abstract] [Full Text] [Related]
12. Commentary on: Do proton pump inhibitors prevent Barrett's esophagus progression to high-grade dysplasia and esophageal adenocarcinoma? An updated meta-analysis.
Li J; Fan Y
J Cancer Res Clin Oncol; 2021 Sep; 147(9):2801-2802. PubMed ID: 34086128
[No Abstract] [Full Text] [Related]
13. Current Status of Chemoprevention in Barrett's Esophagus.
Moayyedi P; El-Serag HB
Gastrointest Endosc Clin N Am; 2021 Jan; 31(1):117-130. PubMed ID: 33213791
[TBL] [Abstract][Full Text] [Related]
14. Proton pump inhibitors for Barrett's oesophagus.
Triadafilopoulos G
Gut; 2000 Feb; 46(2):144-6. PubMed ID: 10644301
[No Abstract] [Full Text] [Related]
15. Do proton pump inhibitors prevent Barrett's esophagus progression to high-grade dysplasia and esophageal adenocarcinoma? An updated meta-analysis.
Chen Y; Sun C; Wu Y; Chen X; Kailas S; Karadsheh Z; Li G; Guo Z; Yang H; Hu L; Zhou Q
J Cancer Res Clin Oncol; 2021 Sep; 147(9):2681-2691. PubMed ID: 33575855
[TBL] [Abstract][Full Text] [Related]
16. The Role of Acid Suppression in Barrett's Esophagus.
Elias PS; Castell DO
Am J Med; 2017 May; 130(5):525-529. PubMed ID: 28159599
[TBL] [Abstract][Full Text] [Related]
17. Daily use of non-steroidal anti-inflammatory drugs is less frequent in patients with Barrett's oesophagus who develop an oesophageal adenocarcinoma.
Tsibouris P; Hendrickse MT; Isaacs PE
Aliment Pharmacol Ther; 2004 Sep; 20(6):645-55. PubMed ID: 15352913
[TBL] [Abstract][Full Text] [Related]
18. Acid suppression and surgical therapy for Barrett's oesophagus.
de Jonge PJ; Spaander MC; Bruno MJ; Kuipers EJ
Best Pract Res Clin Gastroenterol; 2015 Feb; 29(1):139-50. PubMed ID: 25743462
[TBL] [Abstract][Full Text] [Related]
19. Managing Barrett's oesophagus.
Hebbard GS; Nandurkar S
Med J Aust; 2004 Apr; 180(8):375-6. PubMed ID: 15089724
[No Abstract] [Full Text] [Related]
20. Barrett's oesophagus: optimal strategies for prevention and treatment.
Fass R; Sampliner RE
Drugs; 2003; 63(6):555-64. PubMed ID: 12656653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
